134 related articles for article (PubMed ID: 12877092)
1. [Effect of angiotensin II type 1 receptor antagonist on oxidative stress markers in type 2 diabetic patients with hypertension].
Sato N; Kase H; Kato T; Kasai K
Nihon Rinsho; 2003 Jul; 61(7):1245-9. PubMed ID: 12877092
[TBL] [Abstract][Full Text] [Related]
2. [Protective vascular effect of angiotensin receptor blocker (ARB)].
Yamakado M
Nihon Rinsho; 2002 Oct; 60(10):2020-7. PubMed ID: 12397701
[TBL] [Abstract][Full Text] [Related]
3. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
Yu Y; Fukuda N; Yao EH; Matsumoto T; Kobayashi N; Suzuki R; Tahira Y; Ueno T; Matsumoto K
Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
[TBL] [Abstract][Full Text] [Related]
4. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients.
Koh KK; Ahn JY; Han SH; Kim DS; Jin DK; Kim HS; Shin MS; Ahn TH; Choi IS; Shin EK
J Am Coll Cardiol; 2003 Sep; 42(5):905-10. PubMed ID: 12957441
[TBL] [Abstract][Full Text] [Related]
5. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
Bönner G; Fuchs W
Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
[TBL] [Abstract][Full Text] [Related]
6. [Pharma-clinics. The drug of the month. Candesartan (Atacand)].
Kulbertus H
Rev Med Liege; 1999 Jun; 54(6):557-60. PubMed ID: 10446528
[TBL] [Abstract][Full Text] [Related]
7. Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension.
Ono H; Minatoguchi S; Watanabe K; Yamada Y; Mizukusa T; Kawasaki H; Takahashi H; Uno T; Tsukamoto T; Hiei K; Fujiwara H
Hypertens Res; 2008 Feb; 31(2):271-9. PubMed ID: 18360047
[TBL] [Abstract][Full Text] [Related]
8. [Effects of angiotensin II receptor antagonist on insulin sensitivity and sympathetic activity in spontaneously hypertensive rats].
Sasaki K; Kushiro T; Nakagawa S; Kanmatsuse K
Nihon Jinzo Gakkai Shi; 1999 Oct; 41(7):692-6. PubMed ID: 10572394
[TBL] [Abstract][Full Text] [Related]
9. [Candesartan, angiotensin II receptor antagonist].
Sasaguri M; Arakawa K
Nihon Rinsho; 2000 Feb; 58 Suppl 2():144-8. PubMed ID: 11028310
[No Abstract] [Full Text] [Related]
10. Combined treatment with ibuprofen and the AT1 receptor antagonist candesartan in young spontaneously hypertensive rats.
Pollock DM; Morsing P
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S116-9. PubMed ID: 9892151
[TBL] [Abstract][Full Text] [Related]
11. Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure.
Shibasaki Y; Mori Y; Tsutumi Y; Masaki H; Sakamoto K; Murasawa S; Maruyama K; Moriguchi Y; Tanaka Y; Iwasaka T; Inada M; Matsubara H
Clin Nephrol; 1999 Feb; 51(2):83-91. PubMed ID: 10069643
[TBL] [Abstract][Full Text] [Related]
12. [The Diabetic Retinopathy Candesartan Trials (DIRECT) programme].
Ohashi H; Takagi H
Nihon Rinsho; 2005 Jun; 63 Suppl 6():297-301. PubMed ID: 15999723
[No Abstract] [Full Text] [Related]
13. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade.
Schiffrin EL; Touyz RM
J Am Coll Cardiol; 2003 Sep; 42(5):911-3. PubMed ID: 12957442
[No Abstract] [Full Text] [Related]
14. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
Schnack C; Schernthaner G
Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165
[TBL] [Abstract][Full Text] [Related]
15. Differences among angiotensin II type 1 receptor blockers: characteristics of candesartan cilexetil.
Unger T
Blood Press Suppl; 2000; 1():14-8. PubMed ID: 11059630
[TBL] [Abstract][Full Text] [Related]
16. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
17. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
Wei F; Jia XJ; Yu SQ; Gu Y; Wang L; Guo XM; Wang M; Zhu F; Cheng X; Wei YM; Zhou ZH; Fu M; Liao YH;
Heart; 2011 Mar; 97(6):479-84. PubMed ID: 21296780
[TBL] [Abstract][Full Text] [Related]
18. Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats.
Chung S; Park CW; Shin SJ; Lim JH; Chung HW; Youn DY; Kim HW; Kim BS; Lee JH; Kim GH; Chang YS
Nephrol Dial Transplant; 2010 Feb; 25(2):389-99. PubMed ID: 19749146
[TBL] [Abstract][Full Text] [Related]
19. [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
Cice G; Ferrara L; Tagliamonte E; Russo PE; Di Benedetto A; Iacono A
Cardiologia; 1999 Dec; 44(12):1071-6. PubMed ID: 10687258
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction.
Wassmann S; Hilgers S; Laufs U; Böhm M; Nickenig G
Arterioscler Thromb Vasc Biol; 2002 Jul; 22(7):1208-12. PubMed ID: 12117739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
